Synopsis
Synopsis
0
JDMF
0
KDMF
0
VMF
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
Annual Reports
NA
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 74050-97-8
2. Halomonth
3. Haldol Decanoate
4. Neoperidole
5. Kd 136
6. Kd 16
7. Kd-136
8. [4-(4-chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]piperidin-4-yl] Decanoate
9. Ac20pj4101
10. R-13672
11. R-13,672
12. 4-(4-chlorophenyl)-1-(4-(4-fluorophenyl)-4-oxobutyl)piperidin-4-yl Decanoate
13. Decanoic Acid, Ester With 4-(4-(p-chlorophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone
14. Haldol Decanoas
15. Decanoic Acid, 4-(4-chlorophenyl)-1-(4-(4-fluorophenyl)-4-oxobutyl)-4-piperidinyl Ester
16. Depot Haloperidol
17. Haloperidol Depot
18. Halomonth; Haloperidol Decanoate; Kd 136; Kd 16; Neoperidole; R 13762
19. Einecs 277-679-7
20. Haloperidol Decanoate Hcl
21. Unii-ac20pj4101
22. Haldol Dec
23. L-ornithineacetate
24. Halomonth (tn)
25. R 13672
26. Haloperidol-decanoate
27. R 13,672
28. Haloperidol Decanoate [usan:usp:ban:jan]
29. Schembl120575
30. Chembl1200986
31. Chebi:31664
32. Dtxsid50224951
33. Haloperidol Decanoate (jan/usp)
34. Haloperidol Decanoate [mi]
35. Hms3887c07
36. Haloperidol Decanoate [jan]
37. Zinc8214574
38. Haloperidol Decanoate [usan]
39. Bdbm50053408
40. Haloperidol Decanoate [mart.]
41. 4-(4-chlorophenyl)-1-(4-(4-fluorophenyl)-4-oxobutyl)-4-piperidyl Decanoate
42. Akos025392169
43. Haloperidol Decanoate [usp-rs]
44. Haloperidol Decanoate [who-dd]
45. Ks-1419
46. Ncgc00508704-02
47. Haloperidol Decanoate [ep Impurity]
48. Haloperidol Decanoate [orange Book]
49. Haloperidol Decanoate [ep Monograph]
50. Haloperidol Decanoate [usp Impurity]
51. Hy-107969
52. Cs-0031068
53. Ft-0669103
54. Haloperidol Decanoate [usp Monograph]
55. D01898
56. Q27273855
Molecular Weight | 530.1 g/mol |
---|---|
Molecular Formula | C31H41ClFNO3 |
XLogP3 | 7.9 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 16 |
Exact Mass | 529.2759000 g/mol |
Monoisotopic Mass | 529.2759000 g/mol |
Topological Polar Surface Area | 46.6 Ų |
Heavy Atom Count | 37 |
Formal Charge | 0 |
Complexity | 665 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 2 | |
---|---|
Drug Name | Haloperidol decanoate |
PubMed Health | Haloperidol Decanoate (Injection) |
Drug Classes | Antipsychotic |
Drug Label | Haloperidol decanoate USP is the decanoate ester of the butyrophenone, haloperidol. It has a markedly extended duration of effect. It is available in sesame oil in sterile form for intramuscular (IM) injection. The structural formula of haloperidol d... |
Active Ingredient | Haloperidol decanoate |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 50mg base/ml; eq 100mg base/ml |
Market Status | Prescription |
Company | Teva Pharms Usa; Fresenius Kabi Usa; Eurohlth Intl; Agila Speclts |
2 of 2 | |
---|---|
Drug Name | Haloperidol decanoate |
PubMed Health | Haloperidol Decanoate (Injection) |
Drug Classes | Antipsychotic |
Drug Label | Haloperidol decanoate USP is the decanoate ester of the butyrophenone, haloperidol. It has a markedly extended duration of effect. It is available in sesame oil in sterile form for intramuscular (IM) injection. The structural formula of haloperidol d... |
Active Ingredient | Haloperidol decanoate |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 50mg base/ml; eq 100mg base/ml |
Market Status | Prescription |
Company | Teva Pharms Usa; Fresenius Kabi Usa; Eurohlth Intl; Agila Speclts |
Antipsychotic Agents
Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
65
PharmaCompass offers a list of Haloperidol Decanoate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Haloperidol Decanoate manufacturer or Haloperidol Decanoate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Haloperidol Decanoate manufacturer or Haloperidol Decanoate supplier.
PharmaCompass also assists you with knowing the Haloperidol Decanoate API Price utilized in the formulation of products. Haloperidol Decanoate API Price is not always fixed or binding as the Haloperidol Decanoate Price is obtained through a variety of data sources. The Haloperidol Decanoate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Halomonth (TN) manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Halomonth (TN), including repackagers and relabelers. The FDA regulates Halomonth (TN) manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Halomonth (TN) API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Halomonth (TN) manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Halomonth (TN) supplier is an individual or a company that provides Halomonth (TN) active pharmaceutical ingredient (API) or Halomonth (TN) finished formulations upon request. The Halomonth (TN) suppliers may include Halomonth (TN) API manufacturers, exporters, distributors and traders.
click here to find a list of Halomonth (TN) suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Halomonth (TN) DMF (Drug Master File) is a document detailing the whole manufacturing process of Halomonth (TN) active pharmaceutical ingredient (API) in detail. Different forms of Halomonth (TN) DMFs exist exist since differing nations have different regulations, such as Halomonth (TN) USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Halomonth (TN) DMF submitted to regulatory agencies in the US is known as a USDMF. Halomonth (TN) USDMF includes data on Halomonth (TN)'s chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Halomonth (TN) USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Halomonth (TN) suppliers with USDMF on PharmaCompass.
A Halomonth (TN) CEP of the European Pharmacopoeia monograph is often referred to as a Halomonth (TN) Certificate of Suitability (COS). The purpose of a Halomonth (TN) CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Halomonth (TN) EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Halomonth (TN) to their clients by showing that a Halomonth (TN) CEP has been issued for it. The manufacturer submits a Halomonth (TN) CEP (COS) as part of the market authorization procedure, and it takes on the role of a Halomonth (TN) CEP holder for the record. Additionally, the data presented in the Halomonth (TN) CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Halomonth (TN) DMF.
A Halomonth (TN) CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Halomonth (TN) CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Halomonth (TN) suppliers with CEP (COS) on PharmaCompass.
A Halomonth (TN) written confirmation (Halomonth (TN) WC) is an official document issued by a regulatory agency to a Halomonth (TN) manufacturer, verifying that the manufacturing facility of a Halomonth (TN) active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Halomonth (TN) APIs or Halomonth (TN) finished pharmaceutical products to another nation, regulatory agencies frequently require a Halomonth (TN) WC (written confirmation) as part of the regulatory process.
click here to find a list of Halomonth (TN) suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Halomonth (TN) as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Halomonth (TN) API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Halomonth (TN) as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Halomonth (TN) and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Halomonth (TN) NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Halomonth (TN) suppliers with NDC on PharmaCompass.
Halomonth (TN) Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Halomonth (TN) GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Halomonth (TN) GMP manufacturer or Halomonth (TN) GMP API supplier for your needs.
A Halomonth (TN) CoA (Certificate of Analysis) is a formal document that attests to Halomonth (TN)'s compliance with Halomonth (TN) specifications and serves as a tool for batch-level quality control.
Halomonth (TN) CoA mostly includes findings from lab analyses of a specific batch. For each Halomonth (TN) CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Halomonth (TN) may be tested according to a variety of international standards, such as European Pharmacopoeia (Halomonth (TN) EP), Halomonth (TN) JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Halomonth (TN) USP).